Genus plc (GENSY)
OTCMKTS
· Delayed Price · Currency is USD
24.34
+1.34 (5.83%)
At close: Apr 11, 2025
Genus Revenue
Genus had revenue of 336.40M GBP in the half year ending December 31, 2024, a decrease of -3.94%. This brings the company's revenue in the last twelve months to 671.60M, down -0.22% year-over-year. In the fiscal year ending June 30, 2024, Genus had annual revenue of 668.80M, down -3.03%.
Revenue (ttm)
671.60M GBP
Revenue Growth
-0.22%
P/S Ratio
1.67
Revenue / Employee
191.89K GBP
Employees
3,500
Market Cap
1.40B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 668.80M | -20.90M | -3.03% |
Jun 30, 2023 | 689.70M | 96.30M | 16.23% |
Jun 30, 2022 | 593.40M | 19.10M | 3.33% |
Jun 30, 2021 | 574.30M | 22.90M | 4.15% |
Jun 30, 2020 | 551.40M | 62.90M | 12.88% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |